Results 151 to 160 of about 285,474 (314)

Exosome‐Enhanced Injectable Hydrogels: A Comprehensive Review on Their Emerging Role in Wound Healing

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims The escalation of chronic wounds necessitates advanced therapeutic strategies beyond current interventions. Hydrogel dressings, particularly injectable hydrogels, offer promising solutions due to their water absorption capacity, structural resilience, and ease of application.
Mohammad Ebrahim Astaneh, Lalji Baldaniya, Abhayveer Singh, Ahmad Hussen, Alireza Hashemzadeh, Narges Fereydouni   +5 more
wiley   +1 more source

Rate and Equilibrium Constants for the Epimerization of the Endothelin Receptor Antagonist J-104,132 in Aqueous Solution.

, 2001
Michelle Bray, Daniela GORBACHEVA, Hossain Jahansouz, Michael J. Kaufman, Kiyofumi Ishikawa, Nobuo Harada, Kimimasa Suzuki   +6 more
openalex   +2 more sources

LU135252, an endothelin_A receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction [PDF]

, 2000
Quang T. Nguyen, Federico Colombo, Jean L. Rouleau, Jocelyn Dupuis, Angelino Calderone   +4 more
openalex   +1 more source

Endothelin Receptor Antagonists [PDF]

Cardiovascular Drug Reviews, 1994
openaire   +1 more source

The Use of Treprostinil for Bronchopulmonary Dysplasia Associated Pulmonary Hypertension

Pediatric Pulmonology, Volume 61, Issue 1, January 2026.
ABSTRACT Background Treprostinil for the treatment of bronchopulmonary dysplasia‐associated pulmonary hypertension (BPD‐PH) has previously been described in small cohort studies, often used later in the course after failure to improve on other therapies.
Stephanie M. Tsoi, Claire Parker, Elizabeth Colglazier, Shannon Cheung, Mariam Taleb, Hythem Nawaytou, Elena Amin, Jeffrey R. Fineman, Roberta L. Keller   +8 more
wiley   +1 more source

Endothelin Receptor Antagonists for the Treatment of Hypertension: Recent Data from Clinical Trials and Implementation Approach. [PDF]

Curr Cardiol Rep
Manickavasagar R, Krishnan A, Azzam O, Schlaich MP.   +3 more
europepmc   +1 more source

Effect of Endothelin Receptor Antagonists on Clinically Relevant Outcomes after Experimental Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis

Journal of Cerebral Blood Flow and Metabolism, 2015
Kamil G Laban, M. Vergouwen, Rick M Dijkhuizen, E. Sena, M. R. Macleod, Gabriel JE Rinkel, H. B. van der Worp   +6 more
semanticscholar   +1 more source

The Anti-atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin – an Experimental Study

Marianna Stasinopoulou, Nikolaos Kostomitsopoulos, Nikolaos P. E. Kadoglou   +2 more
openalex   +2 more sources

SAT0323 The endothelial-to-mesenchymal transition (ENDOMT) in scleroderma can be prevented by the use of dual endothelin receptor antagonists bosentan and macitentan [PDF]

, 2017
Claudio Corallo, Maurizio Cutolo, Stefano Soldano, A Montella, Concetta De Chirico, Ranuccio Nuti, N. Giordano   +6 more
openalex   +1 more source

Global Resource Disparities Between Pulmonary Hypertension Centers: Results From the International Survey by the PVRI IDDI Access to Care Workstream

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT There is a limited understanding of how pulmonary hypertension (PH) patients are managed worldwide. The Pulmonary Vascular Research Institute (PVRI) Innovative Drug Discovery Initiative (IDDI) global survey attempted to obtain insights into access to PH care in diverse international regions to pave future action plans.
Sasha Z. Prisco, Alexander Kantorovich, Yan Liu, Sandeep Sahay, Roberto Bernardo, Vijay Balasubramanian, J. Usha Raj, Gil Golden, Franz Rischard, the PVRI Innovative Drug Development Initiative Access to Care Workstream   +9 more
wiley   +1 more source